Clinical Trials Browser

Phase 2 × INDUSTRY × ceritinib × Clear all

Lymphoma, B-Cell, Hematologic Neoplasms

NCT02450903 2021-03-30

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

Phase 2 Completed

20 enrolled 12 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02276027 2020-12-16

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

Phase 2 Completed

66 enrolled 18 charts

Thoracic

Adenocarcinoma of Lung

NCT02336451 2020-04-21

Ascend-7

Phase 2 Completed

156 enrolled 39 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02465528 2019-12-27

Ceritinib Rare Indications Study in ALK+ Tumors

Phase 2 Terminated

22 enrolled 16 charts

CNSLymphoidOther hematologic neoplasmPlasma cell

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

NCT01685138 2019-03-26

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Phase 2 Completed

124 enrolled 18 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02638909 2018-04-02

Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

Phase 2 Terminated

4 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Cholangiocarcinoma

NCT01685060 2017-06-19

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Phase 2 Completed

140 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

SIGNATURE

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

Ascend-7

Ceritinib Rare Indications Study in ALK+ Tumors

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib